Ingredient or product comparison
Understanding GHK-Cu Concentration vs Bioavailable Dose
Concentration listed on a product label and the bioavailable dose that reaches target tissue are not the same variable. A 2% GHK-Cu serum applied to intact stratum corneum delivers vastly less peptide-copper complex to dermal fibroblasts than a 0.5% formulatio
This source-based comparison does not add ratings or recommend a winner.
- Concentration listed on a product label and the bioavailable dose that reaches target tissue are not the same variable. A 2% GHK-Cu serum applied to intact stratum corneum delivers vastly less peptide-copper complex to dermal fibroblasts than a 0.5% formulation encapsulated in liposomal carriers or combined with penetration enhancers like DMSO or ethoxydiglycol. The molecular weight of GHK-Cu (approximately 340 Da as the copper complex) sits at the upper threshold for passive dermal penetration. The 500 Da rule-of-thumb suggests peptides above this weight require active delivery mechanisms to cross the epidermis.
- Topical formulations validated in clinical studies typically use 0.1–1% GHK-Cu by weight. A seminal study by Leyden et al. (2005) published in the Journal of Dermatological Treatment used a 0.05% GHK-Cu cream applied twice daily for 12 weeks and reported measurable improvements in skin laxity, fine lines, and dermal density via ultrasound imaging. Demonstrating that low-concentration protocols work when formulation chemistry supports penetration. Higher concentrations (2–3%) appear primarily in wound-healing research where the stratum corneum barrier is compromised, allowing direct access to dermal tissue.
- For injectable or subcutaneous administration in research models, dosing shifts to absolute milligram quantities per injection site. Protocols documented in wound healing studies (Journal of Investigative Dermatology, 2012) administered 0.5–2mg GHK-Cu per subcutaneous injection, delivered in sterile saline or bacteriostatic water at injection volumes of 0.1–0.5mL. Systemic bioavailability following subcutaneous administration is higher than topical routes, but hepatic metabolism and renal clearance still limit circulating half-life to several hours. Making multi-dose protocols standard in extended studies.
- We've observed in our work with research facilities that dosing failures occur not from under-dosing but from formulation instability. GHK-Cu requires a pH range of 5.5–7.0 to maintain copper chelation; formulations outside this range cause peptide-copper dissociation, generating free cupric ions that catalyze lipid peroxidation rather than stimulate collagen synthesis.